Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2019
2019 World Conference on Lung Cancer
Access to all presentations that occur during the 2019 World Conference on Lung Cancer in Barcelona, Spain
Presentation Date(s):- Sept 7 - 10, 2019
- Total Presentations: 2848
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
P1.01 - Advanced NSCLC
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.01-65 - Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy (Now Available)
09:45 - 09:45 | Author(s): Sara Baglivo
- Abstract
Loading...
-
+
P1.16 - Treatment in the Real World - Support, Survivorship, Systems Research
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 0
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.16-09 - Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort
09:45 - 09:45 | Author(s): Giulio Metro
- Abstract
Loading...
-
+
P2.04 - Immuno-oncology
- Type: Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 0
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.04-84 - NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy
10:15 - 10:15 | Presenter: Enrica Capelletto
- Abstract
Loading...
-
+
P2.14 - Targeted Therapy
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 0
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.14-58 - A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
10:15 - 10:15 | Author(s): Filippo De Marinis
- Abstract
Loading...